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Abstract
Background: SYNTAX score II (SS-II) has been demonstrated to predict long-term outcomes 
in unprotected left main or multiple vessels in patients with coronary artery disease. However, 
its prognostic value for patients with ST-segment elevation myocardial infarction (STEMI) 
remains unknown. The poor myocardial perfusion (myocardial blush grade [MBG] 0/1) after 
primary percutaneous coronary intervention (pPCI) has a negative prognostic value in patients 
with STEMI. We aimed to assess SS-II and its possible relationships with MBG 0/1 in patients 
with STEMI treated with pPCI.
Methods: The study included 477 patients with STEMI who underwent pPCI between 
October 2010 and May 2014. SYNTAX Score II and MBG were determined in all patients. 
Myocardial blush grade were divided into MBG 0/1 (poor myocardial perfusion) and MBG 
2/3 (normal myocardial perfusion). Patients were divided into three tertiles: SS-IIlow (£ 20), 
SS-IIintermediate (20–26) and SS-IIhigh (≥ 26).
Results: Compared with the SS-IIintermediate and SS-IIlow tertiles, the SS-IIhigh tertile had more 
MBG 0/1 (46.1%, 32.1% and 21.8%, p < 0.001, respectively). On multivariate logistic re-
gression analysis, SS-II was an independent predictor of MBG 0/1 (hazard ratio 1.084, 95% 
confidence interval 1.050–1.119, p < 0.001). Receiver operating characteristic analysis iden-
tified SS-II > 24 as the best cut-off value predicting MBG 0/1 (sensitivity of 66%, specificity  
of 54%).
Conclusions: High SS-II is an independent predictor of MBG 0/1 in patients with STEMI 
undergoing pPCI. (Cardiol J 2016; 23, 3: 317–323)
Key words: SYNTAX score II, myocardial perfusion, myocardial blush grade, 
ST-segment elevation myocardial infarction, primary percutaneous coronary  
intervention
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Introduction
ST-segment elevation myocardial infarction 
(STEMI) is a major public health problem and 
a leading cause of death all over the world. The 
primary goal in the treatment of STEMI is to open 
infarct-related artery as soon as possible [1]. The 
best way to achieve this goal is rapid determina-
tion and reperfusion of the infarct-related artery by 
means of primary percutaneous coronary interven-
tion (pPCI). Despite providing epicardial coronary 
blood flow, patients may suffer impaired myocar-
dial reperfusion and have poor prognosis [2, 3]. 
Myocardial blush grade (MBG) is a simple visual 
angiographic assessment of myocardial perfusion 
in the infarct area, first described by van’t Hof et 
al. [4]. The occurrence of MBG 0/1 is associated 
with a larger infarct size, lower left ventricular 
ejection fraction (LVEF), increased mortality, and 
congestive heart failure [5–8]. Therefore, MBG is 
often used as an endpoint in clinical trial. Recently, 
the SYNTAX score II (SS-II), as a combination of 
clinical factors and SYNTAX score, can predict 
long-term mortality and morbidity in patients with 
complex coronary artery disease [9–12]. However, 
its prognostic value in STEMI remains unknown.
We hypothesized that SS-II may predict the 
MBG 0/1 in patients with STEMI treated with 
pPCI. We also evaluated the predictive perfor-
mance of the SS-II to predict MBG 0/1 in patients 
with STEMI undergoing pPCI.
Methods
Patient population
We analyzed the clinical and angiographic data 
of 497 consecutive patients diagnosed with acute 
STEMI within 12 h from the symptom onset in 
the period between October 2010 and May 2014. 
Patients undergoing conservative therapy (n = 6), 
thrombolysis (n = 3), or prior coronary artery by-
pass grafting (n = 3), poor imaging quality (n = 8) 
were excluded from the study. Moreover, patients 
with stroke in 3 months, active bleeding, recent 
trauma, or major surgery in 1 month, and con-
traindications to dual antiplatelet therapy to 
12 months were not included in the study. STEMI 
was defined according to the following criteria: 
chest pain lasting longer than 20 min and associ-
ated with ST-segment elevation 1 mm in at least 
2 limb electrocardiographic leads or 2 mm in at least 
2 contiguous precordial leads, or the presence of 
new developed left bundle branch block pattern [1]. 
The diagnosis was confirmed by the elevation in 
troponin levels. The study protocol was approved 
by the hospital’s institutional Review Board.
Stent and post-procedural management
All patients took aspirin (300 mg) and clopi-
dogrel (300–600 mg, according to weight) loading 
dose before diagnostic coronary angiogram. Before 
pPCI, an intravenous bolus injection of heparin 
(100 IU/kg) was administered to achieve a target 
activated clotting time to 250–300 s except for the 
cases of tirofiban administration, whose loading 
dose was 50 IU/kg. If the infarct related artery had 
intracoronary large thrombus burden (thrombus 
score ≥ 3) [13] after predilatation was carried out, 
a thrombectomy catheter was used. Post-dilatation 
after stent implantation was prescribed at the op-
erator’s discretion. All patients were recommended 
100 mg of aspirin and 75 mg of clopidogrel per day 
for at least 1 year. Continuation of antiplatlet and 
other cardiac medications were prescribed at the 
physician’s discretion.
Determination of SS-II and MBG
The SS-II has been previously described in 
detail [11]. Briefly, SS-II includes 2 anatomical vari-
ables (SYNTAX score and left main coronary artery 
disease) and 6 clinical variables (age, creatinine 
clearance (CrCl), LVEF, sex, chronic obstructive 
pulmonary disease, and peripheral vascular dis-
ease). Because patients with STEMI were excluded 
from the initial SYNTAX score algorithm [14], 
therefore, we followed a definition that occluded 
infarct related artery scored as an occluded artery 
of < 3-month duration, which was used in the stud-
ies in STEMI patients [15, 16]. According to the 
baseline diagnostic angiograms, each coronary le-
sion producing ≥ 50% diameter stenosis in vessels 
≥ 1.5 mm was scored separately, which was calcula-
ted using the algorithm available on the web site [17]. 
SYNTAX score (including left main coronary ar-
tery) was assessed by 2 independent and interven-
tional cardiologists blinded to the clinical data, who 
had experience in calculating the SYNTAX score of 
> 100 patients before assisting in our study. The 
k value for interobserver variability that was used 
to estimate the SYNTAX scores was 0.75, while the 
k value for the intraobserver variability was 0.85. 
If there occurred any disagreement regarding the 
SYNTAX scores, the average of the values from 
the 2 readers was used as the final value.
Myocardial perfusion was assessed by MBG 
using the best projection for each coronary artery. 
Duration of cine filming was required to exceed 
3 cardiac cycles in the washout phase to assess the 
www.cardiologyjournal.org 319
Gang Wang et al., SYNTAX score II predicts perfusion in STEMI
washout of myocardial blush. The effectiveness of 
myocardial reperfusion was assessed angiographi-
cally after PCI by MBG as the following [18]: MBG 
0 — failure of dye to enter the microvasculature: 
minimal or no ground glass appearance (“blush”) 
of the myocardium; MBG 1 — dye slowly enters 
but fails to exit the microvasculature: ground glass 
appearance that fails to clear from the microvas-
culature, and dye staining is present > 30 s later; 
MBG 2 — delayed entry and exit of dye from the 
microvasculature and dye is strongly persistent 
after 3 cardiac cycles of the washout phase and 
either does not or only minimally diminishes in 
intensity during wash out; MBG 3 — normal entry 
and exit of dye from the microvasculature. Blush of 
the myocardium that is either gone or only mildly 
persistent at the end of the washout phase. On 
the basis of post-intervention, the patients were 
divided into MBG 0/1 group (poor myocardial perfu-
sion) and MBG 2/3 (normal myocardial perfusion) 
group as previous studies described [7, 18].
Statistical analysis
Continuous data were expressed as mean 
± standard deviation and were compared using 
the ANOVA or Kruskal-Wallis test as appropriate. 
Categorical variables were expressed as percent-
ages and compared by the c2 test or Fisher’s exact 
test as appropriate. Multivariate logistic regression 
analysis was performed to ascertain variables in-
dependently associated with MBG 0/1 after pPCI. 
Variables with a p value of < 0.10 in an univariate 
analysis were included in the model: age, smoking, 
sex, the length of stent in culprit lesion, stent diam-
eter, Killip classification, thrombectomy, tirofiban, 
LVEF, onset to balloon, thrombosis, hypertension, 
diabetes mellitus and SS-II (per 1 point increase). 
Receiver operating characteristic (ROC) curve was 
used to determine the cut-off point for the SS-II 
in the prediction of MBG 0/1. For all analyses, 
a 2-sided p < 0.05 was considered statistically sig-
nificant. Statistical analyses were performed using 
SPSS software (version 17, SPSS Inc., Chicago, IL).
Results
Patients and baseline characteristics
From October 2010 and May 2014, a total of 
477 patients with a mean age of 60.5 ± 10.6 years 
were enrolled in the study. For our analysis, the 
overall SS-II in the studied population did not 
demonstrate a normal distribution, ranging from 
8 to 73, with a median of 24. The SS-II tertiles were 
SS-IIlow £ 20 (n = 158), 20 < SS-IIintermediate < 26 
(n = 151), SS-IIhigh ≥ 26 (n = 168). Baseline clinical 
characteristics of the studied population across the 
3 tertiles were summarized in Table 1. Patients in 
the SS-IIhigh tertile were less likely to be prescribed 
aspirin and clopidogrel at discharge, although there 
was no difference in angiotensin converting enzyme 
inhibitor, beta-blocker and statin. Other clinical char-
acteristic such as diabetes mellitus, previous myocar-
dial infarction, hyperlipidemia, chronic obstructive 
pulmonary disease, family history of coronary artery 
disease were similar among SS-II tertiles.
Angiographically, patients in the SS-IIhigh ter-
tile were more likely to have 3-vessel diseases, 
unprotected left main disease, small vascular 
disease, diffuse disease, calcification disease and 
MBG 0/1 after PCI, compared with lower 2 tertiles. 
Intra-aortic balloon pump, thrombosis disease, 
bifurcation disease, chronic total occlusion dis-
ease, turtous disease, anterior infarction, no-flow 
before pPCI, pre- and post-dilatation, tirofiban and 
thrombectomy did not differ among SS-II tertiles. 
The diameter and length of stents were significant-
ly shorter in SS-IIhigh tertile than those in the other 
2 tertiles (p < 0.001 and p = 0.01, respectively). 
Angiographic and procedural characteristics across 
the 3 tertiles were summarized in Table 2.
Considering MBG 0/1 after pPCI, while fre-
quency of MBG 0/1 in the SS-IIhigh tertile was 
53.0%, whereas the frequency of MBG 0/1 in the 
SS-IIintermediate tertile and SS-IIlow tertile was 41.1% 
and 26.6% separately (p = 0.033 and p < 0.001, 
respectively). Patients in the SS-IIhigh tertile had 
higher MBG 0/1 rates. On multiple regression, 
the SS-II was shown to be an independent predic-
tor for MBG 0/1 (hazard ratio [HR] 1.084, 95% 
confidence interval [CI] 1.050–1.119, p < 0.001). 
Sex (HR 0.368, 95% CI 0.212–0.640, p < 0.001), 
diabetes mellitus (HR 1.774, 95% CI 1.024–3.074, 
p = 0.041), thrombectomy (HR 0.525, 95% CI 
0.319–0.865, p = 0.011), the length of stent in 
culprit lesion (HR 1.041, 95% CI 1.007–1.077, 
p = 0.019) and stent diameter (HR 0.381, 95% CI 
0.268–0.541, p < 0.001) were other independent 
predictors for MBG 0/1 on multivariate logistic 
regression analysis (Table 3). In addition, ROC 
analysis identified SS-II > 24 as the best cut-off 
value predicting MBG 0/1 (sensitivity of 66%, 
specificity of 54%, area under curve: 0.646, 95% 
CI 0.597–0.696, p < 0.001; Fig. 1).
Discussion
In this study, we found that SS-II was indepen-
dently associated with the development of MBG 
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0/1 in the setting of STEMI. SS-II > 24 had a 66% 
sensitivity and 54% specificity for predicting MBG 
0/1 in patients undergoing pPCI.
Many studies show that MBG 0/1 is a signifi-
cant independent predictive marker of mortality, 
microvascular circulation, and myocardial perfusion 
in patients undergoing pPCI after STEMI [19, 20]. 
The previous studies reported MBG 0/1 after pPCI 
was 51.1–66% [18, 21], however we found the fre-
quency of MBG 0/1 was 40.5%. In our study, most 
patients were treated with simple technique pro-
cess in complicated lesions in order to rescue more 
cardiomyocytes as soon as possible. Complicated 
techniques such as mini-crush stenting, culotte 
stenting, V-stenting, or T-stenting were not used 
in bifurcation lesion. Diffused disease was treated 
by using short-stent strategy.
We also found that SS-II was an independent 
predictor of MBG 0/1. Patients in SS-IIhigh tertile 
have a more complex anatomy of coronary artery, 
such as left main lesion, 3-vessels disease, diffuse 
disease, calcification disease, and small vascular 
disease, and increased medical co-morbidities, such 
as peripheral vascular disease, cerebrovascular 
disease, decreased CrCl, older and fewer smokers. 
Several mechanisms may explain the association 
between SS-II and MBG 0/1. First, diffuse disease 
often signifies an impaired microcirculatory resist-
ance index [22]. Second, collateral circulation to the 
microvascular bed will be insufficient if the donor 
artery is also diseased. Third, oxidative stress is 
increased in acute coronary syndrome with the 
severity of coronary artery disease, whereas oxi-
dant stress reduces the vasodilatatory effects of 
nitric oxide, adenosine, and prostacyclin [23–25]. 
Interestingly, there were fewer smokers in the 
patient group with MBG 0/1. This may be related to 
the smokers’ paradox, which means smoking does 
confer a biologically mediated benefit on survival 
[26, 27]. Smoking causes prolonged activation of 
the sympathetic nervous system and acute release 
of epinephrine, these effects could in theory con-
tribute to a mechanism such as myocardial precon-
ditioning. Therefore, to improve microvascular cir-
Table 1. Baseline clinical characteristics according to SYNTAX score II (SS-II) tertiles for primary  
percutaneous coronary intervention.
Variable SS-IIlow, £ 20  
(n = 158)
SS-IIintermediate,  
20–26 (n = 151)
SS-IIhigh, ≥ 26  
(n = 168)
P
Age [years] 52.0 ± 9.0 60.9 ± 8.4 68.2 ± 7.4 < 0.001*
Female 8/158 (5.1%) 28/151 (18.5%) 102/168 (60.7%) < 0.001*
Weight [kg] 71.4 ± 7.0 69.4 ± 7.6 62.5 ± 7.6 < 0.001*
Smoking 60/158 (38.0%) 47/151(31.1%) 31/168 (18.5%) < 0.001*
Diabetes mellitus 21/158 (13.3%) 24/151 (15.9%) 33/168 (19.6%) 0.296
Hypertension 54/158 (34.2%) 72/151 (47.7%) 81/168 (48.2%) 0.017*
Previous MI 5/158 (3.2%) 14/151 (9.3%) 11/168 (6.5%) 0.086
Hyperlipidemia 4/158 (2.5%) 2/151 (1.3%) 5/168 (3%) 0.644
Cerebrovascular disease 10/158 (6.3%) 24/151 (15.9%) 28/168 (16.7%) 0.009*
PVD 0/158 (0%) 5/151 (3.3%) 2/168 (1.2%) 0.035*
COPD 5/158 (3.2%) 4/151 (2.6%) 8/168 (4.8%) 0.565
Family history of CAD 12/158 (7.6%) 8/151 (5.3%) 8/168 (4.8%) 0.519
Left ventricular ejection fraction; 58.6 ± 8.1 54.4 ± 10.4 52.0 ± 11.2 < 0.001*
Killip classification 3–4 3/158 (1.9%) 6/151 (4.0%) 14/168 (8.3%) 0.022*
Creatinine [mL] 67.4 ± 11.9 68.1 ± 16.8 71.7 ± 20.3 0.046*
Clearance of creatine 116.3 ± 25.2 100.1 ± 24.4 73.9 ± 21.2 < 0.001*
Aspirin 157/158 (99.4%) 141/151 (93.4%) 150/168 (89.3%) 0.001*
Clopidogrel 154/158 (97.5%) 142/151 (94.0%) 151/168 (89.3%) 0.018*
ACEI 58/158 (36.7%) 61/151 (40.4%) 54/168 (35.2%) 0.307
Beta-blocker 98/158 (62.0%) 92/151 (60.9%) 100/168 (59.5%) 0.898
Statin 140/158 (88.6%) 133/151 (88.1%) 138/168 (82.1%) 0.171
*p < 0.05; data are expressed in numbers (percentages), mean ± standard deviation, percentages are rounded; MI — myocardial  infarction; 
PVD — peripheral vascular disease; COPD — chronic obstructive pulmonary disease; CAD — coronary artery disease; ACEI — angiotensin-
-converting enzyme inhibitor
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Table 2. Angiographic and procedural characteristic according to SYNTAX score II (SS-II) tertiles for 
percutaneous coronary intervention (PCI).
Variable SS-IIlow, £ 20
(n = 158)
SS-IIintermediate,
20–26 (n = 151)
SS-IIhigh, ≥ 26
(n = 168)
P
Number of diseased vessels: < 0.001*
1-vessel disease 99 (62.7%) 74 (49.0%) 79 (47%)
2-vessel disease 50 (31.6%) 54 (35.8%) 44 (21.2%)
3-vessel disease 9 (5.7%) 23 (15.2%) 45 (26.8%)
Unprotected left main lesion 1/158 (0.6%) 1/151 (0.7%) 4 (2.4%) < 0.001*
Small vascular lesion 3/158 (1.9%) 5/151 (3.3%) 15/168 (8.9%) 0.007*
Chronic total occlusion 3/158 (1.9%) 6/151 (4.0%) 12/168 (7.1%) 0.067
Diffuse lesion 6/158 (3.8%) 14/151 (9.3%) 26/168 (15.5%) 0.002*
Calcification lesion 2/158 (1.3%) 5/151 (3.3%) 17/168 (10.1%) 0.001*
Bifurcation lesion 21/158 (13.3%) 26/151 (17.2%) 27/168 (16.1%) 0.616
Thrombose lesion 115/158 (72.8%) 109/151 (72.2%) 118/168 (70.2%) 0.867
Turtous lesion 0/158 (0%) 2/151 (1.3%) 2/168 (1.2%) 0.472
Intra-aortic balloon pump 0/158 (0%) 0/151 (0%) 3/168 (1.8%) 0.110
Thrombectomy 49/158 (31%) 38/151 (25.2%) 38/168 (22.6%) 0.213
Tirofiban therapy 48/158 (30.4%) 46/151 (30.5%) 54/168 (32.1%) 0.927
Balloon predilatation 106/158 (67.1%) 107/151 (70.9%) 114/168 (67.9%) 0.753
Balloon postdilatation 40/158 (25.3%) 27/151 (17.9%) 31/168 (18.5%) 0.191
No-flow before PCI 134/158 (84.8%) 137/151 (90.7%) 156/168 (92.9%) 0.051
No-flow after PCI 12/158 (7.6%) 19/151 (12.6%) 35/168 (20.8%) 0.002*
Myocardial blush grade 0/1 42/158 (26.6%) 62/151 (41.1%) 89/168 (53.0%) < 0.001*
Total length of stent 25 ± 9.9 23 ± 11.3 20 ± 12.9 0.01*
Stent diameter 2.8 ± 0.9 2.6 ± 1.1 2.3 ± 1.3 < 0.001*
Anterior infarction 64/158 (40.5%) 69/151 (45.7%) 67/168 (39.9%) 0.522
*p < 0.05; values are n/N (%) or mean ± standard deviation
Table 3. Predictors of the myocardial blush grade 0/1.
Variables Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Age 0.989 (0.957–1.022) 0.514 0.993 (0.965–1.022)
Sex 0.351 (0.188–0.655) 0.001 0.368 (0.212–0.640) < 0.001*
The length of stent 1.039 (1.004–1.076) 0.029 1.041 (1.007–1.077) 0.013*
Hypertension 1.236 (0.810–1.886) 0.325 1.230 (0.808–1.873)
Diabetes mellitus 1.694 (0.967–2.968) 0.066 1.774 (1.024–3.074) 0.041*
Stent diameter 0.387 (0.270–0.554) < 0.001 0.381 (0.268–0.541) < 0.001*
Left ventricular ejection fraction 1.006 (0.981–1.031) 0.628 1.005 (0.981–1.031)
Smoking 0.744 (0.461–1.200) 0.226 0.765 (0.477–1.227)
Killip classification 3/4 1.736 (0.620–4.863) 0.294 1.692 (0.609–4.706)
Onset to balloon 1.308 (0.810–2.114) 0.272 1.000 (0.999–1.001)
Thrombectomy 0.525 (0.314–0.877) 0.014 0.525 (0.319–0.865) 0.009*
Tirofiban 0.437 (0.763–1.872) 0.437 1.201 (0.769–1.877)
Thrombosis lesion 0.879 (0.548–1.411) 0.595 0.907 (0.567–1.450)
SYNTAX score II 1.093 (1.034–1.156) 0.002 1.084 (1.050–1.119) < 0.001*
*p < 0.05; OR — odds ratio; CI — confidence interval
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culation, pharmacologic agents such as nicorandil 
and nitroprusside and thrombus aspiration should 
be used in high SS-II tertile in STEMI.
To the best of our knowledge, the relationship 
between SS-II and MBG has not previously been 
investigated. Our results demonstrate for the first 
time the predictive value of SS-II and MBG 0/1 in 
the setting of STEMI treated with pPCI. We found 
that high SS-II was significant and correlated with 
MBG 0/1. In this study, with the help of SS-II, we can 
obtain the predictive information about MBG after 
primary PCI. These results are in agreement with 
studies showing that the SS-II has a risk-predictive 
value in patients undergoing elective PCI [11, 28].
Limitations of the study
Our study has some limitations. First, this 
was a retrospective study based on a relatively 
small number of patients and the study population 
was from a single center. Second, the method of 
measurement of SYNTAX score, which is one of 
the SS-II parameters, presented a limitation. Third, 
because there was a male dominance in patients 
in our study, the results may not be applicable in 
groups with female dominance.
Conclusions
SYNTAX score II, combined of clinical factors 
and SYNTAX score, is an independent predictor 
of the MBG 0/1 in patients with STEMI treated 
with pPCI. In addition, high SS-II may be helpful 
in identifying high-risk patients and determine ap-
propriate treatment strategies. SYNTAX score II 
can be calculated before primary PCI, thereby fa-
cilitating risk prediction for STEMI patients, even 
prior to revascularization.
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